foods and fluids with resultant chemical irritation and bacterial overgrowth could induce chronic inflammation, squamous epithelial hyperplasia, and subsequent dysplasia and carcinoma. 5 Despite these risks, the role of cancer surveillance in patients with achalasia remains unclear. The current American Society of Gastrointestinal Endoscopy and American College of Gastroenterology (ACG) practice guidelines do not recommend routine endoscopic surveillance in patients with achalasia. 6, 7 Per ACG guidelines, surveillance beyond early detection of cancer such as the detection of late complications of achalasia has potential advantages, but more evidence is needed to determine whether the advantages of surveillance practices outweigh the costs. 7 In addition, it is unclear whether surveillance can improve the patients' survival. Some have advocated periodic endoscopic surveillance after 15-20 years of symptoms, as esophageal cancer tends to occur no sooner than 20 years after achalasia symptom onset or in those with end-stage disease. 3, 5, 8 However, the optimal surveillance interval has not yet been determined. The purpose of surveillance is to detect neoplastic lesions at an early stage to facilitate curative treatment. Therefore, it is important to identify patients at risk who can benefit from the surveillance strategy. In addition, effective modalities are needed to identify neoplastic change. The entire esophagus is at risk in patients with achalasia; thus, the entire length should be carefully inspected and sampled. However, endoscopic examination of the esophagus may be difficult in achalasia because the mucosa is often covered with food and saliva, which compromises meticulous inspection. Few studies have evaluated the efficacy of Lugol' s staining in patients with achalasia but have showed unsatisfactory results. 9 Moreover, histological evaluation and assessment of biopsy samples may be challenging because of the presence of chronic inflammatory changes. Identification of morphologic findings or predictive biomarkers that precede the appearance of esophageal cancer may be helpful for a surveillance strategy in patients with achalasia. In this issue of Clinical Endoscopy, the endoscopic and histological features of retention esophagitis in patients with achalasia was reported and the authors suggested the clinical implications of retention esophagitis as a precancerous lesion. 10 Retention esophagitis was defined as the endoscopic finding of stasis or thickened and whitish mucosal changes with the presence of histologically confirmed squamous hyperplasia. Among 37 patients with untreated achalasia, 21 showed both endoscopic and histological findings of retention esophagitis. Patients with retention esophagitis had longer duration of symptoms and showed higher frequency of liquid or food retention in the esophageal lumen than those without retention esophagitis.
In immunohistochemical analyses of two tumor suppressor genes, p53 and p16, and a proliferation marker, Ki-67, p53 expression was found to be more frequent in patients with retention esophagitis than in controls or those without retention esophagitis, whereas Ki-67 expression did not differ among the three groups. 10 A previous study reported that 82% of patients with high-grade dysplasia or cancer showed overexpression of p53 in surveillance biopsies before the development of carcinoma. 11 In addition, overexpression of p53 was more frequently observed in patients with achalasia who developed esophageal cancer. Meanwhile, esophageal epithelial cells in lesions with esophagitis, regardless of the presence of dysplasia or carcinoma, showed more Ki-67-positive cells than normal epithelial cells, suggesting that this marker does not discriminate between patients with and without neoplastic change. 12 A longitudinal cohort study also showed that p53 but not Ki-67 could be used to identify patients with achalasia who are at risk of developing malignancy. 11 Accordingly, it was suggested that patients with achalasia and retention esophagitis may benefit from surveillance endoscopy to detect neoplastic changes. In this study, expression of these markers showed no statistically significant differences between patients without retention esophagitis and controls. 10 Further studies are warranted to confirm whether the presence of retention esophagitis itself, rather than the occurrence of achalasia, is associated with the potential for malignant transformation. In addition, the difference between patients with both endoscopic and histological findings of retention esophagitis and those with endoscopic findings alone should be clarified. Peroral endoscopic myotomy (POEM) is a new, widely accepted option for the treatment of achalasia. 13 A recent study showed that the expression of p53 and Ki-67 decreased after POEM, suggesting that POEM could decreased the potential risk of esophageal squamous cell carcinoma. 14 However, the potential for malignant transformation seems to persist to some degree, even after treatment. 15, 16 Therefore, monitoring should be performed after treatment and symptom resolution in patients with achalasia, particularly in those with other risk factors for the development of esophageal cancer such as smoking and alcohol consumption. In summary, retention esophagitis was associated with higher expression of p53 in patients with achalasia compared to controls or those without retention esophagitis. Patients with achalasia and associated retention esophagitis may be suitable candidates for surveillance endoscopy. Further studies related to the pathogenesis of esophageal cancer in patients with achalasia and the development of effective modalities for surveillance may help in establishing clinical practice guidelines.
